Insights on an IV Antitoxin Infusion for Clostridium Difficile
May 24, 20210
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Host: Neilanjan Nandi, MD
Guest: Jessica Allegretti, MD, MPH
Guest: Jessica Allegretti, MD, MPH
Bezlotoxumab is an IV antitoxin infusion treatment option for Clostridium difficile (C. diff) that’s been shown to reduce recurrence in IBD patients…so why isn’t it being used as much as it should be? Here to share the latest data and insights on bezlotoxumab as a treatment option for IBD patients with C. diff is Dr. Jessica Allegretti, Associate Director of the Crohn's and Colitis Center and Director of the Fecal Microbiota Transplant Program at the Brigham and Women's Hospital in Boston, Massachusetts.
For the best experience, listen in Metacast app for iOS or Android